A new study led by University of Liverpool researchers has confirmed that children with cystic fibrosis (CF) in the US have better lung function than UK children with the disease.
The study suggests that differences do not appear to be explained by early growth or nutrition, but could be linked to differences in the use of early treatments.
This long-term analysis follows a 2015 study comparing UK and US CF populations in the year 2010, which first highlighted potential differences in lung function.
CF is a serious, multi-organ inherited disease characterised by pulmonary infections and progressively declining lung function. Most people with CF die prematurely from their disease through respiratory failure. In the 1960s, median survival in the UK was estimated to be below 10 years of age. In the decades since, outcomes have improved due to multidisciplinary care, nutritional support and new treatments, such that half of the babies born with CF in the UK and the US today can be expected to live at least in to their late 40s.
news.liverpool.ac.uk/2021/0...
Thorax, BMJ Journals. Study Paper:
Mycophenolate instead of Perfinedine or Nintenanib? 
Regular seasonal flare-ups
Waiting anxiously for CT results- Part 2
Organising pneumonia - how soon do the steroids kick in?
